Advantage Alpha Capital Partners LP Takes Position in Guardant Health, Inc. (NASDAQ:GH)

Advantage Alpha Capital Partners LP bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,937 shares of the company’s stock, valued at approximately $343,000.

A number of other large investors have also added to or reduced their stakes in GH. Vanguard Group Inc. grew its stake in Guardant Health by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company’s stock valued at $235,925,000 after purchasing an additional 305,372 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of Guardant Health by 233.5% during the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock valued at $34,701,000 after buying an additional 1,059,104 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Guardant Health by 31.8% during the second quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company’s stock worth $36,973,000 after buying an additional 309,157 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after buying an additional 1,137,482 shares during the last quarter. Finally, Railway Pension Investments Ltd raised its holdings in Guardant Health by 63.8% in the second quarter. Railway Pension Investments Ltd now owns 620,878 shares of the company’s stock valued at $17,931,000 after acquiring an additional 241,800 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on GH. Citigroup raised their price objective on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Craig Hallum lifted their price target on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Leerink Partners lowered their price objective on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Finally, TD Cowen boosted their price target on Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.60.

Guardant Health Trading Down 2.9 %

Guardant Health stock opened at $34.37 on Wednesday. The company has a 50-day simple moving average of $24.42 and a 200-day simple moving average of $27.06. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $37.04. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.85 and a current ratio of 6.22.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Guardant Health’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.73) EPS. On average, sell-side analysts forecast that Guardant Health, Inc. will post -3.38 EPS for the current year.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now directly owns 7,648 shares of the company’s stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 5.50% of the stock is owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.